摘要
变应性鼻炎(AR)是一种常见的过敏性疾病,严重影响患者的生活质量。Th1/Th2失衡是AR发病的免疫学基础,抑制Th2优势是治疗AR的切入点。间充质干细胞(MSCs)是一种具有多向分化潜能的成体干细胞,具有低免疫原特性以及免疫调节能力。本文综述MSC在AR治疗中的研究及其可能机制,期待能为探寻AR治疗新方法提供数据支持。
Allergic rhinitis( AR) is a common allergic disease,which seriously affect the quality of life of patients. Th1/Th2 imbalance is the immunological basis for the pathogenesis of AR,and the suppression of Th2 response is the breakthrough point in the treatment of AR. Mesenchymal stem cells( MSCs) are adult stem cells with multiple differentiation potential,and possess negative immunogenicity and immunomodulation ability. This article reviews the research of MSC in AR therapy and the possible mechanism,and expects to provide data for exploring new methods of AR treatment.
作者
戴玉洋
赵秀丽
DAI Yu-yang;ZHAO Xiu-li(National Institute for Drug Clinical Trial,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第5期482-485,共4页
The Chinese Journal of Clinical Pharmacology
